Promedior Inc

Type: Company
Name: Promedior Inc
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

FDA News Roundup: Merck, UCB, Pfizer, Ipsen, And More

By , associate editorIn the news this week, the FDA recently approved the first immunotherapy for melanoma, as well as drugs for epilepsy and myelodysplastic syndrome. The FDA also cleared several drugs for new indications, QIDP status, and orphan drug ... [Published Pharmaceutical Online - Sep 09 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 4 reports

FDA Names Myelofibrosis Treatment an Orphan Drug

Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for PRM-151, for the treatment of myelofibrosis, ... [Published Drug Discovery and Development - Sep 02 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals for drugs to treat pulmonary fibrosis, a deadly scarring of ... [Published Xconomy - Aug 25 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Treatment Developed by Biologists Shows Promise in Fighting Fibrotic Disease

A decade after first identifying SAP as a key protein in human blood that controls routine tissue-related processes from scarring to healing, Texas A&M biologists continue to make encouraging progress in the fight against fibrotic disease, a broad class ... [Published RT Magazine - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 13 2014 - 1 reports

Wedbush PacGrow Life Sciences Hosts Management Access Conference, Offers Investors Industry Insight

NEW YORK, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Wedbush Securities, one of the nation's leading financial services providers and award-winning equity research firms, will host its Wedbush PacGrow Life Sciences Management Access Conference in New York on August ... [Published Nations Restaurant News - Aug 12 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Treatment Developed By Texas A&M Biologists Shows Promise In Fighting Fibrotic Disease

Contact InformationAvailable for logged-in reporters onlyNewswise — A decade after first identifying serum amyloid P (SAP) as a key protein in human blood that controls routine tissue-related processes from scarring to healing, two Texas A&M University ... [Published Newswise - Aug 08 2014]
First reported Jun 05 2014 - Updated Jun 05 2014 - 1 reports

Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association

LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association ... [Published Business Wire Health News - Jun 05 2014]
First reported May 30 2014 - Updated May 31 2014 - 1 reports

Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior to present positive preliminary phase 2 data for PRM-151 in myelofibrosis at ASCO Meeting. Data showed improvements in patients across all treatment groups with excellent safety profile. ... [Published Business Wire Health News - May 30 2014]
First reported May 15 2014 - Updated May 15 2014 - 1 reports

Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO

LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO ... [Published Business Wire Health News - May 15 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

H.I.G. BioVentures leads Series C round for ForSight VISION5

ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures . Concurrent with the funding, ... [Published PE Hub Blog - Apr 16 2014]

Quotes

...advancing PRM-151 to better meet the needs of patients with myelofibrosis," said Suzanne Bruhn, president and chief executive officer of Promedior. "Based on the encouraging clinical results reported to date in myelofibrosis patients we believe that PRM-151’s novel mechanism of action is compelling with its potential to target and reverse the fundamental bone marrow fibrosis that underlies patients’ disease."
...may be available as advancements in life sciences continue to develop at a swift pace," said Mark Benson, Director of Research, Wedbush Securities. "Our conference will address these issues and provide critical insights through sector specific deep dives, moderated management presentations, one-on-one meetings and informative panels comprised of industry experts."

More Content

All (13) | News (8) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
FDA News Roundup: Merck, UCB, Pfizer, Ipsen, An... [Published Pharmaceutical Online - Sep 09 2014]
FDA Names Myelofibrosis Treatment an Orphan Drug [Published Drug Discovery and Development - Sep 02 2014]
Promedior Receives U.S. Orphan Drug Designation... [Published Fort Mills Times - Sep 02 2014]
Promedior Receives U.S. Orphan Drug Designation... [Published Market Pulse Navigator - Sep 02 2014]
Promedior Receives U.S. Orphan Drug Designation... [Published Business Wire Health News - Sep 02 2014]
Roche To Pay $8.3B For Intermune: Who’s Next In... [Published Xconomy - Aug 25 2014]
Treatment Developed by Biologists Shows Promise... [Published RT Magazine - Aug 19 2014]
Wedbush PacGrow Life Sciences Hosts Management ... [Published Nations Restaurant News - Aug 12 2014]
Treatment Developed By Texas A&M Biologists Sho... [Published Newswise - Aug 08 2014]
Promedior Announces Presentation of Interim Pha... [Published Business Wire Health News - Jun 05 2014]
Promedior to Present Positive Preliminary Phase... [Published Business Wire Health News - May 30 2014]
Promedior Announces Presentation of Interim Pha... [Published Business Wire Health News - May 15 2014]
H.I.G. BioVentures leads Series C round for For... [Published PE Hub Blog - Apr 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Promedior Receives U.S. Orphan Drug Designation... [Published Business Wire Health News - Sep 02 2014]
LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis, a serious, life-limiting cancer characterized by fibrosis of the bone marrow. ...
Promedior Announces Presentation of Interim Pha... [Published Business Wire Health News - Jun 05 2014]
LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association ...
Promedior to Present Positive Preliminary Phase... [Published Business Wire Health News - May 30 2014]
LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior to present positive preliminary phase 2 data for PRM-151 in myelofibrosis at ASCO Meeting. Data showed improvements in patients across all treatment groups with excellent safety profile. ...
Promedior Announces Presentation of Interim Pha... [Published Business Wire Health News - May 15 2014]
LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO ...
H.I.G. BioVentures leads Series C round for For... [Published PE Hub Blog - Apr 16 2014]
ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures . Concurrent with the funding, ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.